HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions

TL;DR

This paper reviews drug interactions between HIV and TB treatments to improve co-infection management and patient outcomes.

Contribution

A comprehensive analysis of drug–drug interactions and adverse effects in HIV–TB co-infection treatment.

Findings

Drug–drug interactions between ART and anti-TB medications can affect treatment efficacy and safety.

Personalized strategies and dose adjustments may minimize adverse outcomes in co-infected patients.

Abstract

The co-occurrence of human immunodeficiency virus (HIV) and tuberculosis (TB) infection poses a significant global health challenge. Treatment of HIV and TB co-infection often necessitates combination therapy involving antiretroviral therapy (ART) for HIV and anti-TB medications, which introduces the potential for drug–drug interactions (DDIs). These interactions can significantly impact treatment outcomes, the efficacy of treatment, safety, and overall patient well-being. This review aims to provide a comprehensive analysis of the DDIs between anti-HIV and anti-TB drugs as well as potential adverse effects resulting from the concomitant use of these medications. Furthermore, such findings may be used to develop personalized therapeutic strategies, dose adjustments, or alternative drug choices to minimize the risk of adverse outcomes and ensure the effective management of HIV and TB co-infection.

Figures